ABBV ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 6, 2022 in the Class Action Filed on Behalf of AbbVie Inc. Limited Shareholders Pharmaceutical Investing
Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months Pharmaceutical Investing
Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10 Pharmaceutical Investing
European Commission Approves Merck's KEYTRUDA® for Patients With Microsatellite Instability-High or Deficient Mismatch Repair Tumors in Five Different Types of Cancer Life Science Investing
European Commission Approves Merck's KEYTRUDA® Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 Life Science Investing
AUPH SHAREHOLDER ALERT: Jakubowitz Law Reminds Aurinia Pharmaceuticals Inc. Shareholders of a Lead Plaintiff Deadline of June 14, 2022 Pharmaceutical Investing
U.S. Food and Drug Administration Approves Camzyos for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms Pharmaceutical Investing
Kessler Topaz Meltzer & Check, LLP - Important Reminder for AbbVie, Inc. Investors of Securities Fraud Class Action Lawsuit Filed on their Behalf Pharmaceutical Investing
